Meeting
2014 ASCO Annual Meeting
Enhancement of cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) with lenalidomide in advanced solid tumors: A phase 1 trial.
Authors
Erin Marie Bertino
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Erin Marie Bertino , Elizabeth L McMichael , Miguel Angel Villalona-Calero , Michael R. Grever , William Edgar Carson III, Gregory Alan Otterson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Clinical Trial Registration Number
NCT01254617
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3044)
DOI
10.1200/jco.2014.32.15_suppl.3044
Abstract #
3044
Poster Bd #
111
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced solid tumors.
First Author: Alberto Bessudo
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca
Poster
2022 ASCO Annual Meeting
Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
First Author: Qing Zhou
Poster
2024 ASCO Annual Meeting
Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.
First Author: Susanna Varkey Ulahannan